Research programme: antibody-drug conjugates - Sorrento Therapeutics

Drug Profile

Research programme: antibody-drug conjugates - Sorrento Therapeutics

Alternative Names: AfDCs - Sorrento Therapeutics; Antibody-formulated drug conjugates - Sorrento Therapeutics; STI-0602; ZV05 ADCs - Sorrento Therapeutics

Latest Information Update: 05 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sorrento Therapeutics
  • Class Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants; Proto oncogene protein c met modulators; Vascular endothelial growth factor receptor-2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer; Non-small cell lung cancer

Most Recent Events

  • 25 Nov 2016 Concortis Biotherapeutics announces intention to submit IND by June 2017 (Concortis Biotherapeutics pipeline, November 2016)
  • 14 Apr 2016 Preclinical trials in Non-small cell lung cancer in USA (Parenteral)
  • 08 Dec 2014 Preclinical trials in Breast cancer in USA (Parenteral) prior to December 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top